Sildosin as a Male Contraceptive Non Hormonal

Not Applicable

Not yet recruiting

• Conditions: Contraception Use
• Interventions: Drug: Oral intake of sildosin; Other: Oral intake of placebo

• Registration Number: NCT07195097
• Lead Sponsor: Benha University

Brief Summary

In all, 200 healthy, sexually active, fertile male candidates will be assigned 100 in silodosin group and 100 in placebo group. Males using other contraceptive methods will be excluded. Follow up data of total spermatozoa per ejaculate, semen volume and Post-ejaculation urinalysis after 2, 6 and 12 weeks of the studied groups will be recorded. The various side effects reported in the study groups after 12 weeks from the start of the study will be recorded.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2025-07-14
• Status Verified: 2025-09
• Study Start: 2025-09-01
• Study First Submitted QC: 2025-09-25
• Last Update Submitted: 2025-09-25
• Study First Posted: 2025-09-26
• Last Update Posted: 2025-09-26
• Primary Completion: 2025-11
• Study Completion: 2025-12-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: Male
• Target Recruitment: 200

Inclusion Criteria

• male sexually active

Exclusion Criteria

• male on oral contraceptives Male with female partner on contraceptives

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Sildosin arm	Oral intake of sildosin	Oral intake of sildosin
Placebo arm	Oral intake of placebo	Oral intake of placebo

Primary Outcome Measures

Name	Time	Method
Pregnancy rate in people treated with sildosin as a male contraceptive	3 months	Pregnancy rate in people treated with sildosin as a male contraceptive treatment